Buy Suven Pharmaceuticals; target of Rs 587: Geojit
Geojit recommended is bullish on Suven Pharmaceuticals recommended buy rating on the stock with a target price of Rs 587 in its research report dated July 02, 2020.03-07-2020
03-07-2020
SUVEN LIFE SCIENCES LTD. - 530239 - Closure of Trading Window
We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 1st July, 2020 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter ending 30th June, 2020, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is for your information and record.30-06-2020
SUVEN LIFE SCIENCES LTD. - 530239 - Clarification sought from Suven Life Sciences Ltd
The Exchange has sought clarification from Suven Life Sciences Ltd on June 26, 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.26-06-2020
Suven Pharma cracks 10% after rallying 61% in previous 5 sessions
ICICI Direct feels despite a significant run up, there is still scope for upside as the company is still trading at significant discount to some leading players in the space dealing with innovators.24-06-2020
SUVEN LIFE SCIENCES LTD. - 530239 - We Enclose A Confirmation For The Financial Year Ended 31St March, 2020, In The Prescribed Format, Pursuant To The SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 Dated 26Th November, 2018. This Is For Your Information And Record.
We confirm that the outstanding long-term borrowing of the Company as on 31st March, 2020 is less than 100 crores and accordingly, the Company is not a ''Large Corporate'' for the purpose of the SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated 26th November, 2018.23-06-2020
Suven Pharmaceuticals posts Q4 net profit of Rs 74.18 crore
The company had posted a net profit of Rs 74.82 crore in the corresponding period of the previous fiscal, Suven Pharma said in a filing to the BSE.18-06-2020
SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Sub: Newspaper advertisement regarding reminder to claim the dividends remaining unpaid/ unclaimed and transfer of unclaimed equity shares of the Company to the Investor Education and Protection Fund (IEPF) Suspense Account: With reference to above subject, please find enclosed the copies of the newspaper advertisements, in connection with the subject referred above as required under Rule 6 (3) of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 read with the Companies Act, 2013 as appeared today i.e. June 18, 2020 in Business Standard and Andhra Prabha (Telugu). The above information will also be hosted on the website of the Company at the following web link: http://www.suven.com/unpaiddividend.aspx This is for your information and record.18-06-2020
SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement - Audited Financial Results of the Company for fourth quarter and FY ended 31st March, 2020 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper advertisements regarding to Audited Financial Results of the Company for fourth quarter and FY ended 31st March, 2020. The advertisements are as appeared on 06th June, 2020 in Business Standard and Andhra Prabha (Telugu). The above information will also be hosted on the website of the Company at: http://www.suven.com/newspaperads.aspx This is for your information and record.06-06-2020
SUVEN LIFE SCIENCES LTD. - 530239 - Outcome Of Board Meeting
With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. June 5, 2020, has taken on record and approved the Audited Standalone and Consolidated Financial Results of the Company under Ind AS for the quarter and for the year ended 31st March, 2020 and approved the following matters.05-06-2020